Comparative Pharmacology
Head-to-head clinical analysis: NUZYRA versus SOLODYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUZYRA versus SOLODYN.
NUZYRA vs SOLODYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omadacycline is a aminomethylcycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
Solodyn (minocycline hydrochloride) is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain.
200 mg intravenously once on day 1, then 100 mg IV once daily; or 200 mg orally once on day 1, then 100 mg orally once daily.
1 mg/kg orally once daily as extended-release tablets; not to exceed 100 mg/day. Alternatively, 1 mg/kg orally once daily as immediate-release tablets; not to exceed 100 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 17-21 hours; supports once-daily dosing.
Terminal elimination half-life: 11-22 hours (mean ~16 hours). Clinically, steady-state reached in 3-4 days; half-life prolonged in renal impairment.
Fecal (approximately 76%) as unchanged drug; renal (approximately 14%) as unchanged drug; biliary excretion is minimal.
Primarily renal (40-70% unchanged) via glomerular filtration; significant biliary/fecal (20-30%) as unchanged drug and metabolites. Enterohepatic recirculation occurs.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic